← The SEC Ephemeris: the whole map
Tris Pharma, Inc. oxybate
In the graph: all 2 documents (5 pages).
- Application
- NDA 220138
- Ticker
- Tris Pharma, Inc.
- Product
- oxybate
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- June 15, 2026 · July 25, 2018
From FDA letters and SEC filings. Not investment or medical advice.